Skip to main content
Seres Therapeutics, Inc. logo

Seres Therapeutics, Inc. — Investor Relations & Filings

Ticker · MCRB ISIN · US81750R2013 LEI · 549300GMXBE5NUWISF13 US Manufacturing
Filings indexed 668 across all filing types
Latest filing 2024-02-16 Director's Dealing
Country US United States of America
Listing US MCRB

About Seres Therapeutics, Inc.

https://www.serestherapeutics.com/

Seres Therapeutics, Inc. is a commercial-stage biotechnology company developing microbiome-based therapeutics. The company's platform creates a novel class of biological drugs, known as live biotherapeutics, which consist of rationally selected consortia of live bacteria. These therapies are designed to modulate the functional properties of the gastrointestinal microbiome to treat and prevent diseases. Seres' development programs target medically vulnerable patient populations, with a focus on preventing bacterial bloodstream and antimicrobial-resistant (AMR) infections, as well as treating gastrointestinal-related immune diseases.

Recent filings

Filing Released Lang Actions
4
Director's Dealing
2024-02-16 English
4
Director's Dealing
2024-02-16 English
4
Director's Dealing
2024-02-16 English
4
Director's Dealing
2024-02-16 English
Major Shareholding Notification 2024
Major Shareholding Notification
2024-02-09 English
8-K
Board/Management Information Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated January 30, 2024, by Seres Therapeutics, Inc. The content announces the setting of the date for the company's 2024 annual meeting of stockholders, details about record dates, and instructions for stockholders to bring business or nominate directors. It does not contain financial statements or detailed financial data. The document is an announcement related to the company's board and shareholder meeting arrangements, specifically about the annual meeting date and proxy information. This fits the category of Board/Management Information (MANG) as it relates to governance events and board-related announcements but is not a full governance report or proxy statement. It is not a report publication announcement or regulatory filing fallback because it contains substantive information about the annual meeting date and nomination procedures. The document length is 4173 characters, which is relatively short but contains substantive event information rather than just a notice of report availability. Therefore, the best classification is MANG with high confidence.
2024-01-30 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.